Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)
Open Access
- 21 August 2025
- journal article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (12) , 3705-3713
Abstract
This study examines associations between blood-based neurodegenerative biomarkers and cognitive functioning in nationally representative samples of older adults in India and the United States. Using data from the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) and the Health and Retirement Study (HRS), we analyzed 4 biomarkers—the ratio of Amyloid beta 42-40 (Aβ42/Aβ40), Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL), and Phosphorylated Tau at Threonine 181 (pTau181)—in relation to cognitive outcomes. Higher levels of GFAP and NfL were associated with worse cognitive function and a greater likelihood of dementia in both populations. GFAP and NfL were also associated with cognitive decline in the HRS, but not in LASI-DAD. Higher Aβ42/Aβ40 ratio was associated with worse cognitive functioning and more dementia in HRS; on the other hand, higher levels of the Aβ42/Aβ40 ratio were significantly linked with better cognitive functioning in LASI-DAD. pTau181 was generally not associated with cognitive functioning in either country. The associations of the whole set of markers with subsequent mortality suggest they may serve as markers for general aging. This article is part of a Special Collection on Cross-National Gerontology.Keywords
Funding Information
- The Health and Retirement Study Biomarker data have been funded by the National Institute on Aging (NIA U01AG009740)
- Bright Focus Foundation (CA2023001)
- National Institute on Aging (R01AG051125, U01AG064948, RF1AG088003, R01AG030153, R01AG042778, P30 AG017265)
This publication has 41 references indexed in Scilit:
- Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the USJAMA Neurology, 2022
- Plasma p‐tau181/Aβ1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ1‐42 and future cognitive declineAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022
- Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assaysAlzheimer's & Dementia, 2021
- Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular diseaseAlzheimer's & Dementia, 2021
- P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET statusAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET statusAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's diseaseAlzheimer's & Dementia, 2020
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's diseaseAnnals of Neurology, 1992